4 Healthcare Stock Stories Making Midweek Medical News

Arena Pharmaceuticals (NASDAQ:ARNA): Closing price $8.10

Arena announced Wednesday that Eisai Limited has submitted a new drug submission for Belviq (lorcaserin HCl) with Health Canada. The drug is being examined in Canada as a supplement to a reduced-calorie diet and increased physical activity for chronic weight management in adult obese patients, or in overweight patients in the presence of a minimum of one additional cardiovascular risk factor, which might include dyslipidemia, hypertension, type 2 diabetes, or sleep apnea. In conjunction with the NDS, Arena will receive a milestone payment of $500,000 from Eisai.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ARNA

Mylan (NASDAQ:MYL): Current price $30.48

Mylan said that its American subsidiary, Mylan Pharmaceuticals, has debuted Norethindrone Tablets USP, 0.35 mg, which is the generic version of Janssen Pharmaceuticals’ Micronor Tablets, 0.35 mg (28-Day Cycle), indicated for the prevention of pregnancy. Mylan’s partner, Famy Care, received a final okay from the FDA for its abbreviated new drug application for this product.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

MYL

Novartis (NYSE:NVS): Closing price $69.60

On Wednesday, Novartis reported late-breaking results indicating that omalizumab attained all its primary and secondary endpoints of a pivotal Phase III safety registration evaluation in chronic spontaneous urticaria, or CSU, a chronic and debilitating form of hives with limited approved treatment options. GLACIAL marks the second of three pivotal Phase III studies that analyze the efficacy and safety of omalizumab in CSU. The study results confirmed the efficacy, safety, and tolerability of omalizumab in patients having refractory CSU, which is a chronic and debilitating skin disease with intractable itch and hives.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

NVS

 Thermo Fisher Scientific (NYSE:TMO): Closing price $83.49

Thermo Fisher said that it has established the China Innovation Center in Shanghai, which meaningfully broadens its research, development, and training capabilities in support of high-growth markets in the Asia-Pacific region. The company has invested $9.5 million in the new Center to support its quickly growing research and development organization, which should contribute between 200 and 300 engineers during the next two to three years. The new facility will include a technology training center to instruct as many as 2,500 customers per year in the use of its industry-leading chromatography and mass spectrometry systems, together with other technologies.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

TMO

Don’t Miss: Can the NFL Make Obamacare Appealing to Young People?